Response to Letter to the Editor: "Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes"
J Clin Endocrinol Metab
.
2020 Jun 1;105(6):e2317-e2318.
doi: 10.1210/clinem/dgaa144.
Authors
Venessa H M Tsang
1
2
3
,
Rachel T McGrath
1
2
,
Roderick J Clifton-Bligh
1
2
3
,
Richard A Scolyer
4
5
,
Valerie Jakrot
4
,
Alexander D Guminski
4
6
,
Georgina V Long
4
6
,
Alexander M Menzies
4
6
Affiliations
1
Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, St Leonards Sydney, Australia.
2
Sydney Medical School, Northern, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
3
Cancer Genetics Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Sydney, NSW, Australia.
4
Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
5
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
6
Departments of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
PMID:
32188993
PMCID:
PMC7170215
DOI:
10.1210/clinem/dgaa144
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents, Immunological*
Diabetes Mellitus, Type 1* / drug therapy
Humans
Nivolumab
Substances
Antineoplastic Agents, Immunological
Nivolumab